2 results
Approved WMOPending
The Primary objective is to assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg/ valsartan 320 mg in patients with essential hypertension (msDBP > 90 mmHg and < 110 mmHg.
Approved WMOCompleted
Primary ObjectiveTo evaluate the efficacy and safety/tolerability of UK-432,097 DPI in adults with moderate to severe COPD (GOLD stage II/III).